This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cloos, J. Articles by Braakhuis, B. J. M. Search for Related Content PubMed PubMed Citation Articles by Cloos, J. Articles by Braakhuis, B. J. M.

Mutagen Sensitivity as a Biomarker for Second Primary Tumors after Head and Neck Squamous Cell Carcinoma¹

Department of Otolaryngology/Head and Neck Surgery [J. C., C. R. L., M. L. T. v. d. S., G. B. S., B. J. M. B.] and Department of Epidemiology and Biostatistics [D. J. K.], University Hospital Vrije Universiteit, 1007 MB, Amsterdam, the Netherlands

The occurrence of second primary tumors after curative treatment of early stage head and neck squamous cell carcinoma negatively influences the overall survival. Our aim was to prospectively evaluate whether mutagen sensitivity (mean number of chromatid breaks per cell in cultured lymphocytes exposed to bleomycin) could be used as a biomarker to predict which patients will develop second malignancies in the respiratory or upper digestive tract. Patients treated for head and neck squamous cell carcinoma (n = 218) were followed for approximately 6 years. Nineteen patients developed a second primary tumor, and each of these patients was matched on age, gender, cumulative smoking, tumor site, and tumor stage to two patients who did not develop any second malignancy. No difference between the groups was found with respect to mutagen sensitivity. Smoking at the time of the index tumor had a significant influence on the occurrence of second primary tumors (log-rank, P = 0.019). There was a significantly (P = 0.005) higher mean breaks-per-cell value in those patients who had developed their second primary tumor 3 years after the first tumor (0.97 ± 0.24; n = 10) compared with early second primary tumor patients (0.69 ± 0.09; n = 9). Conditional on a more than 3-year second primary tumor-free survival (n = 38), there is a significantly (log-rank, P = 0.036) higher probability of a second primary tumor for mutagen-sensitive patients [relative risk, 7.8 (95% confidence interval, 0.99- 61.74; P = 0.05)]. Mutagen sensitivity is a potentional biomarker for the occurrence of ‘late’ second malignancies (>3 years between tumors), and additional studies on the inclusion of this biomarker in chemoprevention trials is commendable because it would greatly improve their efficiency.

This article has been cited by other articles:

				D. L. Chao, C. C. Maley, X. Wu, D. C. Farrow, P. C. Galipeau, C. A. Sanchez, T. G. Paulson, P. S. Rabinovitch, B. J. Reid, M. R. Spitz, et al. Mutagen Sensitivity and Neoplastic Progression in Patients with Barrett's Esophagus: A Prospective Analysis. Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1935 - 1940. [Abstract] [Full Text] [PDF]

				E. Erdei, S.-J. Lee, Q. Wei, L.-E. Wang, Y.-S. Song, D. Bovbjerg, and M. Berwick Reliability of mutagen sensitivity assay: an inter-laboratory comparison Mutagenesis, July 1, 2006; 21(4): 261 - 264. [Abstract] [Full Text] [PDF]

				E. H.C. Dirksen, J. Cloos, B. J.M. Braakhuis, R. H. Brakenhoff, A. J.R. Heck, and M. Slijper Human Lymphoblastoid Proteome Analysis Reveals a Role for the Inhibitor of Acetyltransferases Complex in DNA Double-Strand Break Response Cancer Res., February 1, 2006; 66(3): 1473 - 1480. [Abstract] [Full Text] [PDF]

				J. Cloos, W. P.H. de Boer, M. H.J. Snel, P. van den IJssel, B. Ylstra, C. R. Leemans, R. H. Brakenhoff, and B. J.M. Braakhuis Microarray Analysis of Bleomycin-Exposed Lymphoblastoid Cells for Identifying Cancer Susceptibility Genes Mol. Cancer Res., February 1, 2006; 4(2): 71 - 77. [Abstract] [Full Text] [PDF]

				E. Kowalska, S. A. Narod, T. Huzarski, S. Zajaczek, J. Huzarska, B. Gorski, and J. Lubinski Increased Rates of Chromosome Breakage in BRCA1 Carriers Are Normalized by Oral Selenium Supplementation Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1302 - 1306. [Abstract] [Full Text] [PDF]

				B. J. M. Braakhuis, M. P. Tabor, J. A. Kummer, C. R. Leemans, and R. H. Brakenhoff A Genetic Explanation of Slaughter's Concept of Field Cancerization: Evidence and Clinical Implications Cancer Res., April 15, 2003; 63(8): 1727 - 1730. [Abstract] [Full Text] [PDF]

				M. P. Tabor, R. H. Brakenhoff, H. J. Ruijter-Schippers, J. E. van der Wal, G. B. Snow, C. R. Leemans, and B. J. M. Braakhuis Multiple Head and Neck Tumors Frequently Originate from a Single Preneoplastic Lesion Am. J. Pathol., September 1, 2002; 161(3): 1051 - 1060. [Abstract] [Full Text] [PDF]

				M. L. Bondy, L.-E. Wang, R. El-Zein, M. de Andrade, M. S. Selvan, J. M. Bruner, V. A. Levin, W. K. Alfred Yung, P. Adatto, and Q. Wei {gamma}-Radiation Sensitivity and Risk of Glioma J Natl Cancer Inst, October 17, 2001; 93(20): 1553 - 1557. [Abstract] [Full Text] [PDF]